OMER $5.90<chart> * Omeros Corp. Reports Addl. Data From Phase 2 Trial Of OMS103HP Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.